BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...SVP, chief accounting officer of Allergan plc. Urovant Sciences Ltd. (NASDAQ:UROV), a urology-focused subsidiary of Sumitomo Dainippon...
BioCentury | May 26, 2020
Distillery Therapeutics

Targeting the super elongation complex for diffuse midline glioma

...decreased tumor growth, peritumoral edema and invasion of surrounding anatomic structures. Sanofi (Euronext:SAN; NASDAQ:SNY) and Sumitomo Dainippon...
BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

...Inc. to treat acute, intermittent “off” episodes in patients with Parkinson’s disease. The subsidiary of Sumitomo Dainippon...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...Robinson was president and COO of Paragon Bioservices Inc. Urovant is a urology-focused subsidiary of Sumitomo Dainippon...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

...CMO. He was VP, head of translational medicine at the Boston Biomedical Inc. subsidiary of Sumitomo Dainippon...
...as CFO. He was CFO at Synergy Pharmaceuticals Inc. The pulmonary-focused Altavant Sciences subsidiary of Sumitomo Dainippon...
...NYSE:MRK) from March 2007 to December 2018. BioCentury Staff Applied Therapeutics Inc. twoXAR Inc. Rafael Pharmaceuticals Inc. Addex Therapeutics Ltd. Celyad S.A. Sumitomo Dainippon...
BioCentury | Jan 4, 2020
Finance

All’s well that ends well

...had recovered much of that loss before the fourth quarter. On Dec. 13, SanBio partner Sumitomo Dainippon...
BioCentury | Nov 19, 2019
Clinical News

Big gain for Myovant as oral prostate cancer therapy heads for submission

...Tokyo:4502; NYSE:TAK), which has obtained the drug's approval in Japan as Relumina for uterine fibroids. Sumitomo Dainippon...
BioCentury | Oct 31, 2019
Company News

Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

...the identity of the deal’s fifth subsidiary, which will develop gene therapies for cystic fibrosis. Sumitomo Dainippon...
...time. The last is the CF company unveiled Thursday; it is called Spirovant Sciences (see “Sumitomo Dainippon...
...$0.81 (17%) to $5.46 Thursday; Urovant slipped $0.14 to $9.54. Elizabeth S. Eaton, Staff Writer Roivant Sciences Ltd. Sumitomo Dainippon...
BioCentury | Oct 30, 2019
Company News

Oct. 29 Company Quick Takes: Incyte’s JAK inhibitor beats expectations; plus Sumitomo-Intercept, Merck KGaA-Pfizer, AMAG, Regeneron-Sanofi

...disease, for which it was approved this year. Sumitomo Dainippon returns China rights to Intercept’s Ocaliva Sumitomo Dainippon...
...China of Ocaliva obeticholic acid and returned its territorial rights to Intercept Pharmaceuticals Inc. (NASDAQ:ICPT). Sumitomo Dainippon...
BioCentury | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

...anticipates losing U.S. market exclusivity on antipsychotic Latuda lurasidone and discontinues pancreatic cancer candidate napabucasin. Sumitomo Dainippon...
...SM-13496) napabucasin (BBI608, BB608, BBI-608) Relumina (relugolix, TAK-385) Boston Biomedical Inc. Datavant Duke University Enzyvant Sciences GmbH J.P. Morgan Myovant Sciences GmbH Roivant Sciences GmbH Sumitomo Dainippon...
Items per page:
1 - 10 of 296